BioSpace News Archive

Emmaus Life Sciences, Inc. (OTC: EMMA), a leader in the treatment of sickle cell disease, announced today that it has submitted a temporary license application for Endari ® to the National Health Regulatory Authority in the Kingdom of Bahrain . Approval of the temporary application takes one to two months and is a prerequisi

180 Life Sciences Corp., a clinical-stage biotechnology company with its lead indication in Phase 2b/3, focused on the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain, announced the successful closing of its transaction with KBL Merger Corp IV.

Newomics, a biotechnology company developing and commercializing mass spectrometry solutions for molecular detection applications, today announced the launch of a novel biomedical analysis platform to drive innovation in clinical diagnostics and drug discovery research.

As COVID-19 continues to set new records nationwide, the importance of understanding the difference in accuracy between temporal artery thermometers (TAT) and non-contact devices – now used widely for public temperature screenings – is of paramount importance

Bolt Biotherapeutics, a clinical-stage immuno-oncology company developing tumor-targeted therapies that leverage the power of the innate and adaptive immune systems, today presented the trial design of its ongoing Phase 1/2 clinical trial and preclinical data demonstrating proof-of-concept of its lead clinical drug candidate, BDC-1001.

Precision Genetics, a leader in the molecular laboratory and technology industries, announces today the launch of a new diagnostic test that simultaneously detects SARS-CoV-2 and Influenza A/B strains in upper respiratory tract specimens.

Edmonton-based companies MACH32 and Andau Medical bring to market an aerosol containment device to reduce risk of COVID-19 exposure for healthcare personnel and patients.

With a goal of patient empowerment, the American College of Lifestyle Medicine has announced a Type 2 Diabetes Bill of Rights to raise consumer awareness regarding patient rights to evidence-based Lifestyle Medicine therapeutic approaches as a first-line treatment option. ACLM believes that offering this treatment option is vital at

Aravive, Inc., a clinical-stage oncology company developing transformative therapeutics, announced the Company will host a virtual Ovarian and Renal Cancer Expert Event on Friday, November 20, 2020 from 9:00 a.m. to 10:30 a.m. ET.

Rubius Therapeutics, Inc. (Nasdaq:RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an entirely new class of cellular medicines called Red Cell Therapeutics™, today announced that Pablo J. Cagnoni, M.D., president and chief executive officer, will present at the Jefferies Virtual London Healthcare Conference on Tuesday, November 17, 2020, at 3:15 p.m. GMT/10:15 a.m. EST. A live audio